Neurocutaneous Disorder Market Research Report Information By Type (Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-Weber Syndrome, A-T, VHL), by Diagnosis (MRI, CT, EEG), End-User (Hospitals & Clinics, Diagnostic Centers) – Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Neurocutaneous Disorder Market, by Type

6.1 Introduction

6.2 Tuberous Sclerosis (TS)

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Neurofibromatosis (NF)

6.2.1 Neurofibromatosis Type 1 (NF1),

6.2.2 Neurofibromatosis Type 2 (NF2),

6.2.3 Schwannomatosis

6.4 Sturge-Weber Syndrome Disease

6.2.1 Type 1

6.2.2 Type 2

6.2.3 Type 3

6.5 Von Hippel-Lindau Disease (VHL)

6.5.1 Market Estimates & Forecast, 2020–2027

6.5 Ataxia-Telangiectasia (A-T)

6.5.1 Market Estimates & Forecast, 2020–2027

6.5 Others

6.5.1 Market Estimates & Forecast, 2020–2027

Chapter 7. Global Neurocutaneous Disorder Market, by Diagnosis

7.1 Introduction

7.2 Skull Radiography

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Magnetic Resonance Imaging (MRI)

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Computed Tomography (CT) Scan

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Electroencephalogram (EEG)

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Genetic Tests (blood testing)

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Biopsy

7.7.1 Market Estimates & Forecast, 2020–2027

7.6 Others

7.6.1 Market Estimates & Forecast, 2020–2027

Chapter 8. Global Neurocutaneous Disorder Market, by treatment

8.1 Introduction

8.2 Medication

8.2.1 Antiepileptic

8.2.2 Beta-Antagonist Eye Drops

8.2.3 Carbonic Anhydrase Inhibitors

8.2.4 Adrenergic Eye Drops

8.2.5 Miotic Eye Drops

8.2.6 Others

8.3 Laser Therapy

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Surgical Procedures

8.4.1 Focal Cortical Resection

8.4.2 Hemispherectomy

8.4.3 Corpus Callosotomy

8.4.4 Trabeculectomy

8.4.5 Filtration Surgery

8.4.6 Cyclocryotherapy

8.4.7 Vagal Nerve Stimulation (VNS)

8.4.8 Others

8.5 Others

8.5.1 Market Estimates & Forecast, 2020–2027

Chapter 9. Global Neurocutaneous Disorder Market, by End-User

9.1 Introduction

9.2 Hospital & Clinics

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

9.3.2 Market Estimates & Forecast, 2020–2027

9.4 Others

9.4.1 Market Estimates & Forecast, 2020–2027

Chapter 10. Global Neurocutaneous Disorder Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 The Middle East

10.5.2 Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Valeant Pharmaceuticals International, Inc.

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Allergan

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Syneron Medical Ltd.

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Medtronic Plc

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cutera, Inc.

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 St Jude Medical, Inc.

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Pfizer

11.7.1 Overview

11.7.2 Types Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Neurocutaneous Disorder Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Neurocutaneous Disorder Industry Synopsis, 2020–2027

Table 2 Neurocutaneous Disorder Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Neurocutaneous Disorder Market, by Region, 2020–2027, (USD Million)

Table 4 Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 5 Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 7 Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 8 North America Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 9 North America Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 11 North America Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 13 U.S. Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 15 US Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 21 South America Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

Table 40 Middle East & Africa Neurocutaneous Disorder Market, by Type, 2020–2027, (USD Million)

Table 41 Middle East & Africa Neurocutaneous Disorder Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 Middle East & Africa Neurocutaneous Disorder Market, by Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Neurocutaneous Disorder Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Neurocutaneous Disorder Market

Figure 3 Segmentation Market Dynamics for Neurocutaneous Disorder Market

Figure 4 Global Neurocutaneous Disorder market Share, by Type 2020

Figure 5 Global Neurocutaneous Disorder market Share, by Diagnosis 2020

Figure 6 Global Neurocutaneous Disorder market Share, by Treatment 2020

Figure 7 Global Neurocutaneous Disorder market Share, by End-User, 2020

Figure 8 Global Neurocutaneous Disorder market Share, by Region, 2020

Figure 9 North America Neurocutaneous Disorder market Share, by Country, 2020

Figure 10 Europe Neurocutaneous Disorder market Share, by Country, 2020

Figure 11 Asia Pacific Neurocutaneous Disorder market Share, by Country, 2020

Figure 12 Middle East & Africa Neurocutaneous Disorder market Share, by Country, 2020

Figure 13 Global Neurocutaneous Disorder market: Company Share Analysis, 2020 (%)

Figure 14 Valeant Pharmaceuticals International, Inc.: Key Financials

Figure 15 Valeant Pharmaceuticals International, Inc. Segmental Revenue

Figure 16 Valeant Pharmaceuticals International, Inc.: Geographical Revenue

Figure 17 Allergan: Key Financials

Figure 18 Allergan: Segmental Revenue

Figure 19 Allergan: Geographical Revenue

Figure 20 Syneron Medical Ltd.: Key Financials

Figure 21 Syneron Medical Ltd.: Segmental Revenue

Figure 22 Syneron Medical Ltd.: Geographical Revenue

Figure 23 Medtronic Plc: Key Financials

Figure 24 Medtronic Plc: Segmental Revenue

Figure 25 Medtronic Plc: Geographical Revenue

Figure 26 Cutera: Key Financials

Figure 27 Cutera: Segmental Revenue

Figure 28 Cutera Geographical Revenue

Figure 29 St Jude Medical, Inc.: Key Financials

Figure 30 St Jude Medical, Inc.: Segmental Revenue

Figure 31 St Jude Medical, Inc.: Geographical Revenue

Figure 32 Pfizer Inc.: Key Financials

Figure 33 Pfizer Inc.: Segmental Revenue

Figure 34 Pfizer Inc.: Geographical Revenue